

**Title:** Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure.

**Authors:** Pooja Dewan MBBS<sup>1</sup>

Alice Jackson MBChB<sup>1</sup>

Carolyn S.P. Lam MBBS PhD<sup>2,3,4</sup>

Marc A. Pfeffer MD PhD<sup>5</sup>

Faiez Zannad MD PhD<sup>6</sup>

Bertram Pitt MD<sup>7</sup>

Scott D. Solomon MD<sup>5</sup>

John J.V. McMurray MD<sup>1</sup>

**Affiliations:** <sup>1</sup>BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; <sup>2</sup>National Heart Center Singapore and Duke–National University of Singapore, Singapore; <sup>3</sup>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; <sup>4</sup>The George Institute for Global Health, Australia; <sup>5</sup>Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston; <sup>6</sup>INSERM

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/ejhf.1776](https://doi.org/10.1002/ejhf.1776)

CIC 1433 NI-CRCT (Cardiovascular and Renal Clinical Trialists) F-  
CRIN network Université de Lorraine and CHRU Nancy France;  
<sup>7</sup>Division of Cardiology, University of Michigan, Ann Arbor, MI.

**Corresponding author:**

Professor John J.V. McMurray,  
British Heart Foundation Cardiovascular Research Centre,  
University of Glasgow,  
126 University Place,  
Glasgow, G12 8TA,  
United Kingdom.  
Tel: +44 141 330 3479  
Fax: +44 141 330 6955  
Email: [john.mcmurray@glasgow.ac.uk](mailto:john.mcmurray@glasgow.ac.uk)

**Word count (excluding references): 892**

Recently, the Prospective comparison of ARni (Angiotensin receptor-neprilysin inhibitor) with Arb (angiotensin receptor blocker) Global Outcomes in heart failure (HF) with preserved ejection fraction trial (PARAGON-HF) suggested that women might obtain more benefit than men from sacubitril/valsartan, compared with valsartan, in HF with preserved ejection fraction (HFpEF).<sup>1-3</sup> However, the picture is more complicated as there was also an interaction between left ventricular ejection fraction (LVEF) and the effect of sacubitril/valsartan.<sup>2</sup> Patients with a LVEF at or below the median (57%) seemed to gain more benefit from than sacubitril/valsartan those with a LVEF above the median.<sup>2</sup> To make matters more complex still, it is well known that the distribution of LVEF is different in women and men, with women, on average, having a higher LVEF than men, be it in the general population or in individuals with heart failure.<sup>4-6</sup> Despite a higher LVEF, women with HFpEF had worse systolic function, as assessed by tissue Doppler echocardiography, compared to men with HFpEF.<sup>7</sup> To further investigate the relationship between sex, LVEF and treatment in HF, we explored the effect of three different neurohumoral modulators in large trials which provide data on clinical outcomes in patients with HF, across the full range

of LVEF, incorporating the three commonly described HF phenotypes – HF with reduced ejection fraction (HFrEF - LVEF <40%), HF with preserved ejection fraction (HFpEF – LVEF >50%) and HF with mid-range ejection fraction (HFmrEF - LVEF 40-50%).<sup>8</sup>

We pooled individual patient-level data from: 1) Three trials using an angiotensin receptor blocker - The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) – the CHARM-Alternative and CHARM-Added trials in HFrEF and the CHARM-Preserved trial in HFmrEF/HFpEF.<sup>9</sup> 2) Three trials using a mineralocorticoid receptor antagonist (MRAs) – two HFrEF trials, the Randomised Aldactone Evaluation Study (RALES), Eplerenone in Mild Patients Hospitalization and Survival Study in HF trial (EMPHASIS-HF) and one HFmrEF/HFpEF trial - the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial (TOPCAT).<sup>10-12</sup> Only TOPCAT patients from the Americas were included. 3) Two trials using sacubitril-valsartan – the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in HF trial (PARADIGM-HF) in HFrEF and PARAGON-HF in HFmrEF/HFpEF.<sup>1,13</sup>

Cox proportional hazards modelling was used to analyse i) the primary composite outcome (first occurrence of HF hospitalization or cardiovascular death), ii) first HF hospitalization and iii) cardiovascular death. Likelihood ratio tests were used to report i) two-way interactions between treatment and sex and ii) three-way interaction between treatment, sex and LVEF. LVEF, modelled as a fractional polynomial, and its interaction with treatment using the best fit model for each drug category (based on the primary composite outcome)

was examined with the `mfpi` command in Stata. Models were stratified by trial for MRAs and sacubitril-valsartan. All analyses were conducted using Stata ver.16.

This present analysis included 2400, 1938 and 4311 women and 5199, 4229 and 8884 men in the candesartan, MRA and sacubitril-valsartan trials, respectively [Table 1]. Overall mean LVEF (%) was  $38.9 \pm 14.9$ ,  $35.3 \pm 16.0$  and  $39.7 \pm 15.1$ , respectively. Women had a higher mean LVEF, with the difference compared to men 6.3%, 9.4% and 10.3%, respectively. Women had a lower incidence of the primary composite outcome (and its components) in each of the treatment and control groups.

In keeping with prior reports from the CHARM Program and TOPCAT, as well as a recent analysis of PARADIGM-HF and PARAGON-HF, we found that that treatment with an ARB, MRA or ARNI may be of benefit beyond the upper limit of LVEF eligibility used in contemporary HFrEF clinical trials (40%) and may extend to what has been termed HFmrEF (LVEF 40-49%) and even to the lower part of the LVEF range currently categorized as HFpEF.<sup>2,6,14,15</sup> Importantly, the benefit of each treatment seemed to extend to a higher LVEF in women, compared to men [Figure 1]. There was no difference in efficacy of therapy between men and women with HFrEF.

Because these are *post hoc* analyses, they are only hypothesis generating. However, the fact that all three neurohumoral modulating therapies demonstrated the same sex-related pattern of response raises the possibility that the differential response between women and men identified in PARAGON-HF may be real rather than due to the play of chance, although

interpretation of PARAGON-HF is more complex as it had an active comparator compared with a placebo control in the other trials. Despite this consistent observation in the trials examined, the biological basis for such a finding is uncertain. As detailed elsewhere, the possibilities include sex-related differences in cardiac remodelling in response to blood pressure, age and other stimuli, and differences in age-related arterial stiffening, which is more pronounced in women than men.<sup>3</sup> Women may also have other evidence of contractile dysfunction, compared with men, for a given ejection fraction.<sup>3</sup> Natriuretic peptide levels are lower in women with HFpEF, than in men and women may have reduced cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signalling compared with men, especially after the menopause.<sup>3</sup> The possibility that women with HF might benefit from treatment to a higher level of LVEF than previously considered could be of great clinical importance. Women with HF have fewer treatment options than men with HF because HFmrEF and HFpEF are the predominant HF phenotypes in women and no therapy has been approved by regulatory authorities for either of these phenotypes.<sup>6</sup> More research on this matter is clearly required.

### References

1. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Veldhuisen DJ van, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen H-D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ,

Zhou J, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2019;1–11.

2. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai A, Lund LH, Koeber L, Anand I, Sweitzer NK, Linssen G, Merkely B, Arango JL, Vinereanu D, Chen C-H, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJ V. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. *Circulation* 2019;
3. McMurray JJ V, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal S V, Shah AM, Shah SJ, Shi VC, Veldhuisen DJ van, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. *Circulation* 2019;
4. Dewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. *J Am Coll Cardiol* 2019;**73**:29–40.
5. Dewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, Mckelvie RS, Meara EO, Pfeffer

MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJ V. *Circulation : Heart Failure* Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. 2019;

6. Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. *JACC Cardiovasc Imaging*. 2015; 8: 656-65.
7. Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. *Eur J Heart Fail*. 2014; 16: 535-42.
8. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P van der, Filippatos G, McMurray JJV, Aboyans V, Achenbach S, Agewall S, Al-Attar N, Atherton JJ, Bauersachs J, Camm AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution . *Eur J Heart Fail* John Wiley and Sons



Ltd; 2016;**18**:891–975.

9. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J, Yusuf S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. *Lancet* 2003;**362**:759–766.
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999;**341**:709–717.
11. Zannad F, McMurray JJV, Krum H, Veldhuisen DJ Van, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* Massachusetts Medical Society; 2011;**364**:11–21.
12. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2014;**370**:1383–1392.
13. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. *N Engl J Med* Massachusetts Medical Society; 2014;**371**:993–1004.

14. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. *Eur Heart J* Oxford University Press; 2016;**37**:455–462.
15. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. *Eur J Heart Fail*. 2018; 20: 1230-1239.



**Table 1: Interaction of treatment and left ventricular ejection fraction in men and women with heart failure.**

	Overall	Men	Women	p-interaction*	p-interaction <sup>§</sup>	p-interaction <sup>#</sup>
<b>Candesartan</b>						
Number of patients	7599	5199	2400			
Age – mean ± SD	65.5 ± 11.1	64.4 ± 10.9	67.8 ± 11.1			
Ejection fraction – mean ± SD	38.9 ± 14.9	36.9 ± 14.0	43.2 ± 15.8			
<b>Primary composite outcome</b>						
Event rate per 100 pt. yrs. (95% CI)						
Placebo	13.8 (13.1 – 14.6)	14.3 (13.4 – 15.2)	12.9 (11.7 – 14.3)			
Candesartan	11.6 (10.9 – 12.2)	11.9 (11.1 – 12.7)	10.8 (9.7 – 12.0)			
Hazard ratio (95% CI)	0.84 (0.78 – 0.91) <0.001	0.84 (0.76 – 0.92)	0.84 (0.73 – 0.97)	0.9939	0.0146	0.0649
<b>HF hospitalization</b>						
Event rate per 100 pt. yrs. (95% CI)						
Placebo	9.7 (9.1 – 10.3)	9.7 (9.0 – 10.5)	9.6 (8.6 – 10.8)			
Candesartan	7.6 (7.1 – 8.2)	7.6 (7.0 – 8.3)	7.5 (6.6 – 8.6)			
Hazard ratio (95% CI)	0.79 (0.72 – 0.87) <0.001	0.79 (0.70 – 0.89)	0.79 (0.66 – 0.94)	0.9824	0.0566	0.1361
<b>Cardiovascular death</b>						
Event rate per 100 pt. yrs. (95% CI)						
Placebo	7.2 (6.7 – 7.7)	7.6 (7.0 – 8.3)	6.3 (5.5 – 7.2)			
Candesartan	6.3 (5.9 – 6.8)	6.7 (6.2 – 7.4)	5.4 (4.7 – 6.2)			

Hazard ratio (95% CI)	<i>0.88 (0.79 – 0.97)</i> <i>0.013</i>	0.89 (0.79 – 1.00)	0.86 (0.70 – 1.04)	0.7531	<i>0.3454</i>	0.1876
<b>Mineralocorticoid receptor blocker (MRA)</b>						
Number of patients	<i>6167</i>	4229	1938			
Age – mean ± SD	<i>68.5 ± 9.8</i>	67.8 ± 9.6	70.1 ± 10.1			
Ejection fraction – mean ± SD	<i>35.3 ± 16.0</i>	32.3 ± 14.0	41.7 ± 18.1			
<b>Primary outcome</b>						
Event rate per 100 pt. yrs. (95% CI)						
Placebo	<i>20.0 (18.8 – 21.2)</i>	21.7 (20.2 – 23.3)	16.8 (15.0 – 18.7)			
MRA	<i>14.0 (13.1 – 15.0)</i>	15.2 (14.0 – 16.4)	11.8 (10.5 – 13.4)			
Hazard ratio (95% CI)	<i>0.70 (0.64 – 0.77)</i> <i>&lt;0.001</i>	0.70 (0.63 – 0.77)	0.71 (0.60 – 0.84)	0.8089	<i>0.0074</i>	0.0682
<b>HF hospitalization</b>						
Event rate per 100 pt. yrs. (95% CI)						
Placebo	<i>13.9 (13.0 – 14.9)</i>	14.8 (13.5 – 16.1)	12.3 (10.9 – 14.0)			
MRA	<i>9.4 (8.7 – 10.2)</i>	9.9 (9.0 – 11.0)	8.4 (7.3 – 9.8)			
Hazard ratio (95% CI)	<i>0.69 (0.62 – 0.77)</i> <i>&lt;0.001</i>	0.68 (0.60 – 0.78)	0.70 (0.57 – 0.85)	0.8567	<i>0.0077</i>	0.1006
<b>Cardiovascular death</b>						
Event rate per 100 pt. yrs. (95% CI)						
Placebo	<i>9.7 (9.0 – 10.5)</i>	10.8 (9.8 – 11.8)	7.6 (6.6 – 8.9)			
MRA	<i>7.0 (6.4 – 7.7)</i>	8.1 (7.3 – 9.0)	5.1 (4.2 – 6.1)			
Hazard ratio (95% CI)	<i>0.73 (0.65 – 0.82)</i> <i>&lt;0.001</i>	0.75 (0.65 – 0.86)	0.67 (0.53 – 0.84)	0.4100	<i>0.9333</i>	0.9494

<b>Sacubitril-valsartan</b>						
Number of patients		13195	8884	4311		
Age – mean ± SD		67.0 ± 11.3	65.6 ± 11.3	70.0 ± 10.6		
Ejection fraction – mean ± SD		39.7 ± 15.1	36.3 ± 13.4	46.6 ± 16.0		
<b>Primary outcome</b>						
Event rate per 100 pt. yrs. (95% CI)	RAAS inhibitor	11.4 (10.8 – 11.9)	12.3 (11.6 – 13.0)	9.6 (8.8 – 10.5)		
	Sacubitril-valsartan	9.5 (9.1 – 10.0)	10.6 (9.9 – 11.2)	7.6 (6.9 – 8.4)		
Hazard ratio (95% CI)		0.84 (0.78 – 0.90) <0.001	0.86 (0.79 – 0.93)	0.79 (0.70 – 0.91)	0.3452	0.0424 0.0034
<b>HF hospitalization</b>						
Event rate per 100 pt. yrs. (95% CI)	RAAS inhibitor	7.4 (7.0 – 7.9)	7.6 (7.1 – 8.2)	7.0 (6.3 – 7.8)		
	Sacubitril-valsartan	6.2 (5.9 – 6.6)	6.7 (6.2 – 7.3)	5.3 (4.7 – 5.9)		
Hazard ratio (95% CI)		0.84 (0.77 – 0.92) <0.001	0.89 (0.80 – 0.98)	0.76 (0.65 – 0.88)	0.1003	0.0560 0.0057
<b>Cardiovascular death</b>						
Event rate per 100 pt. yrs. (95% CI)	RAAS inhibitor	5.6 (5.3 – 6.0)	6.6 (6.1 – 7.1)	3.8 (3.3 – 4.3)		
	Sacubitril-valsartan	4.7 (4.4 – 5.0)	5.4 (5.0 – 5.9)	3.3 (2.9 – 3.8)		
Hazard ratio (95% CI)		0.83 (0.76 – 0.92) <0.001	0.81 (0.73 – 0.91)	0.89 (0.73 – 1.08)	0.4461	0.2136 0.5871

\*Interaction between treatment and sex.

§Interaction between treatment and ejection fraction modelled as a fractional polynomial.

#Three-way interaction between treatment, sex and ejection fraction.  
Hazard ratios were stratified for trial in case of MRAs and sacubitril-valsartan.

## Figure legend

**Figure 1: Variation of treatment effect with left ventricular ejection fraction in heart failure.**

Dotted curves show normalized distribution of LVEF in men (blue) and women (red). Solid blue (men) and red (women) lines show a continuous hazard ratio for the primary composite and its components, according to treatment group the range of LVEF included.

The shaded areas represent the 95% confidence intervals:

Primary outcome (HF hospitalization/cardiovascular death)

- A) candesartan vs placebo
- B) MRA vs placebo
- C) sacubitril-valsartan vs RAAS inhibitor.

Heart failure hospitalization

- D) candesartan vs placebo
- E) MRA vs placebo
- F) sacubitril-valsartan vs RAAS inhibitor

Cardiovascular death


- G) candesartan vs placebo
- H) MRA vs placebo




l) sacubitril-valsartan vs RAAS inhibitor

Author Manuscript


## Cardiovascular death - Candesartan




# Heart failure hospitalization - Candesartan



Author Manuscript





# Cardiovascular death - Sacubitril-valsartan




Author Manuscript

# Heart failure hospitalization - Sacubitril-valsartan










# Heart failure hospitalization - MRA



## Primary outcome - MRA

